AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10068928
Drug: UVA1 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UVA1 therapy (4 weeks post-treatment)
Trial: 28419855
Drug: Silymarin (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (700 mg, 3 times daily for 48 weeks)
Trial: 26030948
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of ultrasound and TENS
Trial: 26030948
Drug: Monotherapy (either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (either ultrasound or TENS)
Trial: 20857170
Drug: Lapatinib 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1,500 mg PO daily
Trial: 19500005
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with drugs
Trial: 11158764
Drug: Gemifloxacin (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin (320 mg)
Trial: 15078000
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg)
Trial: 11214127
Drug: Terbutaline 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 0.5 mg as needed
Trial: 25850968
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg/day (monotherapy)
Trial: 25850968
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg/day + Metformin ≥1500 mg/day (add-on therapy)
Trial: 16869994
Drug: Fermented gruel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented gruel with live L. plantarum 299v
Trial: 12616127
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant human erythropoietin (r‐HuEPO) 300 IU/kg body weight plus 100 mg iron intravenously
Trial: 12616127
Drug: Placebo medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medication and iron
Trial: 9499605
Drug: Pentavalent antimony
RxNorm normalized name: Pentavalent Antimony
DrugBank: Pentavalent Antimony (DB13047)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent antimony compound (sodium stibogluconate)
Trial: 3793333
Drug: diltiazem (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diltiazem (60 mg)
Trial: 20959578
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestin (combined conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d)
Trial: 10473054
Drug: hCRH (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCRH (1 microg/kg/h in saline) infusion
Trial: 29741923
Drug: PRP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP treatment (n = 27)
Trial: 29231359
Drug: Acupoint pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint pressure therapy applied at uterine orifice dilation of 2 to 3 cm, 5 to 6 cm, 7 to 8 cm, and 9 to 10 cm.
Trial: 29231359
Drug: Acupoint pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint pressure therapy (observation group)
Trial: 29231359
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no acupoint pressure therapy)
Trial: 17262713
Drug: Hyperosmolar gel
RxNorm normalized name: HYPEROSMOTIC LAXATIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperosmolar gel
Trial: 17262713
Drug: Iso-osmolar gel
RxNorm normalized name: iso-sulfan blue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iso-osmolar gel
Trial: 15274066
Drug: Subcutaneous interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon-alpha (9 MU daily) - Arm A
Trial: 15274066
Drug: Subcutaneous interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon-alpha (9 MU daily) plus oral 13-cis retinoic acid (1 mg/kg) - Arm B
Trial: 25799356
Drug: Nasal high-flow
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high-flow (NHF) system at 30 L/minute
Trial: 25799356
Drug: Nasal high-flow
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high-flow (NHF) system at 50 L/minute
Trial: 25799356
Drug: Oxygen at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen at 5 L/minute through a nasal cannula (NC5 group)
Trial: 24195548
Drug: Dolutegravir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir (50 mg) plus abacavir-lamivudine once daily (DTG-ABC-3TC group)
Trial: 24195548
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with efavirenz-tenofovir disoproxil fumarate-emtricitabine once daily (EFV-TDF-FTC group)
Trial: 19682096
Drug: Dental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental treatment under a comprehensive dental programme
Trial: 9869105
Drug: High-dose Epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Epirubicin (EPI) 120 mg/m2 plus Cisplatin (CP) 60 mg/m2
Trial: 9869105
Drug: Vinorelbine (VNR)
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine (VNR) 25 mg/m2 plus Cisplatin (CP) 60 mg/m2
Trial: 7657856
Drug: Cimetidine (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1600 mg per day)
Trial: 7657856
Drug: Famotidine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (80 mg per day)
Trial: 2621066
Drug: St. Thomas'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. Thomas' hospital solution (potassium concentration 20 mmol/l) - group A
Trial: 2621066
Drug: Ringer's injection
RxNorm normalized name: COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's injection (potassium concentration 4 mmol/l) - group B
Trial: 4834097
Drug: Induction dose
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction dose of methohexitone 1.0 mg/kg
Trial: 4834097
Drug: Induction dose
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction dose of methohexitone 1.4 mg/kg
Trial: 28667230
Drug: Combination povidone
RxNorm normalized name: Povidone
DrugBank: Povidone (DB11061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination povidone iodine and sodium fluoride dental varnish
Trial: 19154844
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual activities and medications)
Trial: 7594512
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose TNFR:Fc (10 mg/m2 i.v.)
Trial: 7594512
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose TNFR:Fc (60 mg/m2 i.v.)
Trial: 7594512
Drug: TNFR:Fc (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFR:Fc (both doses)
Trial: 7033351
Drug: Sucralfate (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (500 mg tablets, two tablets after meals and at bedtime)
Trial: 7033351
Drug: Placebo (tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (tablets after meals and at bedtime)
Trial: 28803925
Drug: Swedish screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swedish screening protocol (2-year interval, PSA cut-off 3.0 ng/ml)
Trial: 28803925
Drug: Lower PSA
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower PSA threshold in Finland (PSA cut-off <4.0 ng/ml)
Trial: 28803925
Drug: Finnish screening
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finnish screening protocol (4-year interval, PSA cut-off 4.0 ng/ml)
Trial: 29048238
Drug: Vitamin B12-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12-containing ointment (M-treatment)
Trial: 29048238
Drug: Glycerol-petrolatum-based emollient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol-petrolatum-based emollient cream (C-treatment)
Trial: 24226805
Drug: Ultrasound-assisted catheter-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-assisted catheter-directed thrombolysis (USAT) with 10 to 20 mg recombinant tissue plasminogen activator over 15 hours
Trial: 24226805
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin alone (heparin group)
Trial: 8291919
Drug: CPT-11 (irinotecan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT-11 (irinotecan) regimen A (100 mg/m2 weekly)
Trial: 8291919
Drug: CPT-11 (irinotecan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT-11 (irinotecan) regimen C (200 mg/m2 every 3-4 weeks)
Trial: 28591084
Drug: Local ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local ketamine 1 mg/kg instilled in the wound
Trial: 28591084
Drug: Intramuscular ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketamine 1 mg/kg
Trial: 28591084
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 mL normal saline instilled in the wound)
Trial: 25394438
Drug: Sodium (Na)
DrugBank: Sodium nitrate (DB15952)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium (Na) bicarbonate infusion
Trial: 20952003
Drug: 300 U
RxNorm normalized name: lactase 3300 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 U botulinum toxin-A intradetrusor injections excluding the trigone (detrusor arm)
Trial: 20952003
Drug: 200 U
RxNorm normalized name: lipase 1200 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 U intradetrusor plus 100 U intratrigonal injections (combined arm)
Trial: 11299091
Drug: Soybean protein
RxNorm normalized name: Soybean protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean protein intake (upper quartile: 8.7-35.2 g/day)
Trial: 8203790
Drug: Daflon 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daflon 500 mg (group D, n = 60)
Trial: 8203790
Drug: Daflon 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daflon 500 mg (group D)
Trial: 3441747
Drug: Intradermal (i.d.)
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (i.d.) administration of 2 micrograms
Trial: 3441747
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) administration of 20 micrograms
Trial: 3441747
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of 2 micrograms
Trial: 3441747
Drug: Intradermal (i.d.)
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (i.d.) and Intramuscular (i.m.) routes
Trial: 29504671
Drug: HFNC 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFNC 6 L/minute
Trial: 24985962
Drug: Enzalutamide and
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide and abiraterone in combination with standard-of-care
Trial: 23615395
Drug: Theobromine (0.0011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theobromine (0.0011 mol/l)
Trial: 23615395
Drug: NaF toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaF toothpaste slurry (0.0789 mol/l F)
Trial: 19818785
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of immunosuppressive therapy (azathioprine) and 3 infusions of infliximab
Trial: 19027269
Drug: Combination antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antipsychotic treatment
Trial: 15705990
Drug: Control subjects
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control subjects (no ICS treatment)
Trial: 10372700
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA; 5 mg/day)
Trial: 10372700
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus MPA (0.625 mg/day conjugated equine estrogen and 5 mg/day MPA)
Trial: 1801057
Drug: Conventional low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional low protein diet (0.6 g/kg/day protein, 800 mg phosphate; n = 33)
Trial: 1801057
Drug: Low phosphate
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low phosphate diet (providing approximately 1000 mg phosphate plus an orally administered phosphate binder, minimum protein intake 0.8 g/kg/day; n = 30)
Trial: 1801057
Drug: Control (minimum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (minimum protein intake 0.8 g/kg/day, no phosphate restriction; n = 32)
Trial: 6859212
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (no. 1 pink tint)
Trial: 6859212
Drug: Monofocal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monofocal treatment
Trial: 6859212
Drug: Bifocal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifocal treatment
Trial: 30904839
Drug: Twice a
RxNorm normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice a week programme (n=20)
Trial: 28166914
Drug: Anti-tubercular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tubercular therapy (ATT) for 6 months
Trial: 28166914
Drug: No anti-tubercular
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anti-tubercular therapy (no ATT)
Trial: 27016906
Drug: Conservative Treatment
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative Treatment (CT), n = 42
Trial: 27016906
Drug: Surgical Treatment
RxNorm normalized name: SURGICAL AIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical Treatment (ST), n = 42
Trial: 27016906
Drug: Conservative Treatment
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative Treatment (CT), n = 41 (after follow-up)
Trial: 27016906
Drug: Surgical Treatment
RxNorm normalized name: SURGICAL AIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical Treatment (ST), n = 40 (after follow-up)
Trial: 11772148
Drug: Indapamide sustained-release
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide sustained-release (SR) 1.5 mg/day
Trial: 3365665
Drug: High-dose metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoclopramide (8 mg/kg)
Trial: 3365665
Drug: Low-dose metoclopramide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose metoclopramide (0.8 mg/kg)
Trial: 21960669
Drug: Intravenous peramivir
RxNorm normalized name: Peramivir
DrugBank: Peramivir (DB06614)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous peramivir (600 mg)
Trial: 21960669
Drug: Oral oseltamivir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oseltamivir (75 mg)
Trial: 21960669
Drug: Oral rimantadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rimantadine (100 mg)
Trial: 21960669
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of peramivir with oseltamivir or rimantadine
Trial: 19046761
Drug: 5-grass-pollen sublingual
RxNorm normalized name: Timothy grass pollen extract Sublingual Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-grass-pollen sublingual immunotherapy tablets (300 IR)
Trial: 9651560
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pravastatin
Trial: 8582132
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) infusion at 24 mU kg‐1 min‐1
Trial: 8582132
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) infusion at 12 mU kg‐1 min‐1
Trial: 8582132
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) infusion at 6 mU kg‐1 min‐1
Trial: 1978069
Drug: Nimodipine 120
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine 120 mg per day
Trial: 69882
Drug: Monoamine-oxidase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoamine-oxidase inhibitors (clorgyline and pargyline)
Trial: 31407967
Drug: Clinical model
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical model using predictors (clinical stage N2 or N3, presence of axillary lymphadenopathy at US after NAC, tumor size reduction less than 50% at MRI, Ki‐67 negativity, hormone receptor positivity, and HER2 negativity)
Trial: 26005768
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment in the municipality (control group)
Trial: 329848
Drug: Glycopyrrolate 0.2
RxNorm normalized name: glycopyrrolate 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate 0.2 mg + Neostigmine 1.0 mg
Trial: 329848
Drug: Atropine +
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine + Neostigmine (exact dosage not specified)
Trial: 27838943
Drug: Betamethasone (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (two consecutive doses of 12 mg intramuscularly, 24 hours apart)
Trial: 25459995
Drug: Probiotic strains
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic strains (Bifidobacterium longum, B. lactis, Lactobacillus acidophilus, L. rhamnosus, L. plantarum, and Pediococcus pentosaceus) at a dose of 10^9 colony forming units/g, administered twice daily for 1 week.
Trial: 25459995
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered twice daily for 1 week.
Trial: 23787721
Drug: Valsartan and
RxNorm normalized name: valsartan and aliskiren
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan and an ACE inhibitor (dual RAAS blockade)
Trial: 8659771
Drug: Intravenous tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tramadol (150 mg)
Trial: 8659771
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (2 mg bolus + 0.2 mg/h continuous infusion)
Trial: 30389347
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for insomnia (CBT-I) combined with the modern neuroscience approach
Trial: 29171486
Drug: Cerebrolysin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin treatment
Trial: 19155895
Drug: Oral sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sedation (10 mg of oxycodone and 1 mg of lorazepam)
Trial: 19155895
Drug: Intravenous sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sedation (100 micrograms fentanyl and 2 mg midazolam)
Trial: 19155895
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of oral sedation to intravenous sedation
Trial: 8617132
Drug: Cisapride 10
RxNorm normalized name: cisapride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 10 mg four times a day for three days
Trial: 1418064
Drug: Crystalline lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Crystalline lactulose (60 g/d for 30 days)
Trial: 6319087
Drug: Oral digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral digoxin (0.25 mg/day)
Trial: 22375947
Drug: Routine medical
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medical treatment (treatment as usual)